The DOK1 Knockout HeLa Polyclonal Cells constitute a precisely engineered CRISPR/Cas9-edited polyclonal knockout cell population in which the DOK1 gene has been disrupted across a pool of HeLa cells. This polyclonal population harbors a diverse array of loss-of-function mutations at the target locus, allowing researchers to study DOK1-dependent phenotypes in a genetically heterogeneous background that averages out potential clonal biases.
The host HeLa cell line is an immortalized epithelial model originating from human cervical adenocarcinoma. It remains a cornerstone of cancer biology research due to its robust proliferation, extensive characterization, and compatibility with a wide range of molecular and cellular assays. The cervical cancer origin renders these cells particularly relevant for dissecting oncogenic signaling cascades and tumor suppressor pathways that are deregulated in cervical carcinoma.
DOK1 (downstream of tyrosine kinase 1) is an adaptor protein that exerts negative regulation over receptor tyrosine kinase (RTK) and immunoreceptor signaling pathways. In response to ligand engagement of upstream receptors??such as the insulin receptor (INSR), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), T cell receptor (TCR), B cell receptor (BCR), and cytokine receptors including IL-2 and IL-4??DOK1 undergoes tyrosine phosphorylation. This modification creates docking sites for key negative regulators: RAS p21 protein activator 1 (RASA1, also known as RasGAP), which accelerates GTP hydrolysis on RAS, and SH2-containing inositol-5′-phosphatase (INPP5D/SHIP), which hydrolyzes phosphatidylinositol-3,4,5-trisphosphate. Consequently, DOK1 attenuates downstream MAPK/ERK (via RASA1) and PI3K/AKT (via SHIP) signaling, thereby suppressing cell proliferation, migration, and survival. Additionally, DOK1 physically interacts with non-receptor tyrosine kinases ABL1, SRC, and FYN, integrating feedback from diverse receptor systems.
In the HeLa cervical adenocarcinoma background, DOK1 likely functions as a tumor suppressor by tempering mitogenic and survival signals emanating from hyperactive RTKs and inflammatory cytokines. Loss of DOK1 in this polyclonal knockout model allows for the systematic investigation of its role in restraining MAPK/ERK-driven cell cycle progression and PI3K/AKT-mediated anti-apoptotic responses. The model is particularly valuable for exploring how DOK1 deficiency may promote drug resistance or amplify cytokine-dependent signaling networks implicated in cervical cancer progression and immune evasion.
This polyclonal DOK1 knockout cell population supports a wide array of research applications, including mechanistic studies of tumor suppression, negative feedback regulation of growth factor and immune signaling, and the identification of therapeutic vulnerabilities. Typical assays involve western blotting to monitor levels of phospho-DOK1, total DOK1, phospho-ERK, and phospho-AKT; co-immunoprecipitation to detect physical interaction between DOK1 and RASA1 or SHIP; cell proliferation (MTT, BrdU), migration, and invasion assays; flow cytometry for cell cycle and apoptosis analysis; and phospho-signaling arrays to profile global pathway alterations. For further information, please contact Ascent Research.
